Open AccessHigh bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - The tamip study
Author(s) -
Mohammed Balghith
Publication year - 2012
Publication title -
heart views
Language(s) - English
Resource type - Journals
eISSN - 0976-5123
pISSN - 1995-705X
DOI - 10.4103/1995-705x.102145
Subject(s) - medicine , tirofiban , abciximab , conventional pci , timi , myocardial infarction , percutaneous coronary intervention , cardiology , bolus (digestion) , aspirin , st elevation , thrombolysis , st segment
Primary percutaneous coronary intervention (PCI) has been shown to be an effective therapy for patients with acute myocardial infarction (MI). Glycoprotein (GP) IIb/IIIa receptor blockers reduce thrombotic complications in patients undergoing PCI. Most available data relate to Reopro, which has been registered for this indication. GP IIb/IIIa reduce unfavorable outcome in U/A and non ST-elevation myocardial infarction (STEMI) patients. Only few studies focused on high dose Aggrastat for STEMI patients in the emergency department (ED) before PCI. The aim is to increase the patency during the time awaiting coronary angioplasty in patients with acute MI.